51 related articles for article (PubMed ID: 34878824)
1. LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response.
Faletti S; Osti D; Ceccacci E; Richichi C; Costanza B; Nicosia L; Noberini R; Marotta G; Furia L; Faretta MR; Brambillasca S; Quarto M; Bertero L; Boldorini R; Pollo B; Gandini S; Cora D; Minucci S; Mercurio C; Varasi M; Bonaldi T; Pelicci G
Sci Transl Med; 2021 Dec; 13(623):eabf7036. PubMed ID: 34878824
[TBL] [Abstract][Full Text] [Related]
2. Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells.
Zhao J; Jin W; Yi K; Wang Q; Zhou J; Tan Y; Xu C; Xiao M; Hong B; Xu F; Zhang K; Kang C
Pharmacol Res; 2021 Sep; 171():105764. PubMed ID: 34246782
[TBL] [Abstract][Full Text] [Related]
3. Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma.
Barone A; Sengupta R; Warrington NM; Smith E; Wen PY; Brekken RA; Romagnoli B; Douglas G; Chevalier E; Bauer MP; Dembowsky K; Piwnica-Worms D; Rubin JB
Oncotarget; 2014 Oct; 5(20):9811-22. PubMed ID: 25238146
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of LSD1 induces ferroptosis through the ATF4-xCT pathway and shows enhanced anti-tumor effects with ferroptosis inducers in NSCLC.
Du L; Yang H; Ren Y; Ding Y; Xu Y; Zi X; Liu H; He P
Cell Death Dis; 2023 Nov; 14(11):716. PubMed ID: 37923740
[TBL] [Abstract][Full Text] [Related]
5. OGDH and Bcl-xL loss causes synthetic lethality in glioblastoma.
Nguyen TT; Torrini C; Shang E; Shu C; Mun JY; Gao Q; Humala N; Akman HO; Zhang G; Westhoff MA; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38483541
[TBL] [Abstract][Full Text] [Related]
6. Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion.
Pallavi R; Gatti E; Durfort T; Stendardo M; Ravasio R; Leonardi T; Falvo P; Duso BA; Punzi S; Xieraili A; Polazzi A; Verrelli D; Trastulli D; Ronzoni S; Frascolla S; Perticari G; Elgendy M; Varasi M; Colombo E; Giorgio M; Lanfrancone L; Minucci S; Mazzarella L; Pelicci PG
Nat Commun; 2024 Jan; 15(1):828. PubMed ID: 38280853
[TBL] [Abstract][Full Text] [Related]
7. Heat Shock Proteins in Glioblastoma Biology: Where Do We Stand?
Iglesia RP; Fernandes CFL; Coelho BP; Prado MB; Melo Escobar MI; Almeida GHDR; Lopes MH
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752169
[TBL] [Abstract][Full Text] [Related]
8. Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance.
Bailleul J; Vlashi E
Antioxid Redox Signal; 2023 Nov; 39(13-15):957-979. PubMed ID: 37022791
[No Abstract] [Full Text] [Related]
9. Modeling glioblastoma heterogeneity as a dynamic network of cell states.
Larsson I; Dalmo E; Elgendy R; Niklasson M; Doroszko M; Segerman A; Jörnsten R; Westermark B; Nelander S
Mol Syst Biol; 2021 Sep; 17(9):e10105. PubMed ID: 34528760
[TBL] [Abstract][Full Text] [Related]
10. Targeting of REST with rationally-designed small molecule compounds exhibits synergetic therapeutic potential in human glioblastoma cells.
Panina SB; Schweer JV; Zhang Q; Raina G; Hardtke HA; Kim S; Yang W; Siegel D; Zhang YJ
BMC Biol; 2024 Apr; 22(1):83. PubMed ID: 38609948
[TBL] [Abstract][Full Text] [Related]
11. The integrated stress response in cancer progression: a force for plasticity and resistance.
Lines CL; McGrath MJ; Dorwart T; Conn CS
Front Oncol; 2023; 13():1206561. PubMed ID: 37601686
[TBL] [Abstract][Full Text] [Related]
12. PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING-Type I Interferon Signaling in Glioblastoma.
Mondal I; Das O; Sun R; Gao J; Yu B; Diaz A; Behnan J; Dubey A; Meng Z; Eskandar E; Xu B; Lu RO; Ho WS
Cancer Res; 2023 Aug; 83(15):2527-2542. PubMed ID: 37219874
[TBL] [Abstract][Full Text] [Related]
13. Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Alejo S; Palacios BE; Venkata PP; He Y; Li W; Johnson JD; Chen Y; Jayamohan S; Pratap UP; Clarke K; Zou Y; Lv Y; Weldon K; Viswanadhapalli S; Lai Z; Ye Z; Chen Y; Gilbert AR; Suzuki T; Tekmal RR; Zhao W; Zheng S; Vadlamudi RK; Brenner AJ; Sareddy GR
Neuro Oncol; 2023 Jul; 25(7):1249-1261. PubMed ID: 36652263
[TBL] [Abstract][Full Text] [Related]
14. Activating transcription factor 4: a regulator of stress response in human cancers.
Wu D; Liang J
Front Cell Dev Biol; 2024; 12():1370012. PubMed ID: 38601083
[TBL] [Abstract][Full Text] [Related]
15. GFI1B and LSD1 repress myeloid traits during megakaryocyte differentiation.
Venhuizen J; van Bergen MGJM; Bergevoet SM; Gilissen D; Spruijt CG; Wingens L; van den Akker E; Vermeulen M; Jansen JH; Martens JHA; van der Reijden BA
Commun Biol; 2024 Mar; 7(1):374. PubMed ID: 38548886
[TBL] [Abstract][Full Text] [Related]
16. Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinib.
Zong Y; Tao Z; Jiang S; Wang M; Yu W
Discov Oncol; 2024 Mar; 15(1):89. PubMed ID: 38538885
[TBL] [Abstract][Full Text] [Related]
17. GPR68-ATF4 signaling is a novel prosurvival pathway in glioblastoma activated by acidic extracellular microenvironment.
Williams CH; Neitzel LR; Cornell J; Rea S; Mills I; Silver MS; Ahmad JD; Birukov KG; Birukova A; Brem H; Tyler B; Bar EE; Hong CC
Exp Hematol Oncol; 2024 Jan; 13(1):13. PubMed ID: 38291540
[TBL] [Abstract][Full Text] [Related]
18.
López-Tobón A; Shyti R; Villa CE; Cheroni C; Fuentes-Bravo P; Trattaro S; Caporale N; Troglio F; Tenderini E; Mihailovich M; Skaros A; Gibson WT; Cuomo A; Bonaldi T; Mercurio C; Varasi M; Osborne L; Testa G
Sci Adv; 2023 Dec; 9(48):eadh2726. PubMed ID: 38019906
[TBL] [Abstract][Full Text] [Related]
19. Lysine-specific demethylase 1 as a therapeutic cancer target: observations from preclinical study.
Johnson JD; Alejo S; Jayamohan S; Sareddy GR
Expert Opin Ther Targets; 2023; 27(12):1177-1188. PubMed ID: 37997756
[TBL] [Abstract][Full Text] [Related]
20. Demethylase-independent roles of LSD1 in regulating enhancers and cell fate transition.
Zeng C; Chen J; Cooke EW; Subuddhi A; Roodman ET; Chen FX; Cao K
Nat Commun; 2023 Aug; 14(1):4944. PubMed ID: 37607921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
